NXTMH Stock Overview
Nexstim Plc, a medical technology company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||€3.85|
|52 Week High||€5.90|
|52 Week Low||€3.62|
|1 Month Change||-12.40%|
|3 Month Change||-8.33%|
|1 Year Change||-15.38%|
|3 Year Change||-72.00%|
|5 Year Change||-99.48%|
|Change since IPO||-99.98%|
Recent News & Updates
Nexstim's (HEL:NXTMH) Promising Earnings May Rest On Soft Foundations
Nexstim Plc ( HEL:NXTMH ) announced strong profits, but the stock was stagnant. Our analysis suggests that shareholders...
At €4.73, Is Nexstim Plc (HEL:NXTMH) Worth Looking At Closely?
Nexstim Plc ( HEL:NXTMH ), might not be a large cap stock, but it saw a decent share price growth in the teens level on...
Is Nexstim (HEL:NXTMH) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
|NXTMH||FI Medical Equipment||FI Market|
Return vs Industry: NXTMH exceeded the Finnish Medical Equipment industry which returned -39.9% over the past year.
Return vs Market: NXTMH exceeded the Finnish Market which returned -20.7% over the past year.
|NXTMH Average Weekly Movement||5.6%|
|Medical Equipment Industry Average Movement||9.3%|
|Market Average Movement||5.1%|
|10% most volatile stocks in FI Market||8.2%|
|10% least volatile stocks in FI Market||3.4%|
Stable Share Price: NXTMH is not significantly more volatile than the rest of Finnish stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: NXTMH's weekly volatility (6%) has been stable over the past year.
About the Company
Nexstim Plc, a medical technology company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company’s proprietary SmartFocus technology with 3D navigation is the navigated transcranial magnetic stimulation (TMS) approach that is used for therapeutic and diagnostic applications. It offers NBT system, a navigated brain therapy system for the treatment of major depression and chronic neuropathic pain; and NBS system, a navigated brain stimulation system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim Fundamentals Summary
|NXTMH fundamental statistics|
Is NXTMH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NXTMH income statement (TTM)|
|Cost of Revenue||€1.22m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Feb 27, 2023
|Earnings per share (EPS)||0.50|
|Net Profit Margin||28.59%|
How did NXTMH perform over the long term?See historical performance and comparison
Is NXTMH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NXTMH?
Other financial metrics that can be useful for relative valuation.
|What is NXTMH's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does NXTMH's PE Ratio compare to its peers?
|NXTMH PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
BIOBV Biohit Oyj
REG1V Revenio Group Oyj
ALEMG Euromedis Groupe
Price-To-Earnings vs Peers: NXTMH is good value based on its Price-To-Earnings Ratio (7.8x) compared to the peer average (29.5x).
Price to Earnings Ratio vs Industry
How does NXTMH's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: NXTMH is good value based on its Price-To-Earnings Ratio (7.8x) compared to the European Medical Equipment industry average (24.8x)
Price to Earnings Ratio vs Fair Ratio
What is NXTMH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||7.8x|
|Fair PE Ratio||6.3x|
Price-To-Earnings vs Fair Ratio: NXTMH is expensive based on its Price-To-Earnings Ratio (7.8x) compared to the estimated Fair Price-To-Earnings Ratio (6.3x).
Share Price vs Fair Value
What is the Fair Price of NXTMH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NXTMH (€3.85) is trading below our estimate of fair value (€12.73)
Significantly Below Fair Value: NXTMH is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Nexstim forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NXTMH's earnings are forecast to decline over the next 3 years (-31.4% per year).
Earnings vs Market: NXTMH's earnings are forecast to decline over the next 3 years (-31.4% per year).
High Growth Earnings: NXTMH's earnings are forecast to decline over the next 3 years.
Revenue vs Market: NXTMH's revenue is expected to decline over the next 3 years (-4.9% per year).
High Growth Revenue: NXTMH's revenue is forecast to decline over the next 3 years (-4.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NXTMH's Return on Equity is forecast to be high in 3 years time (31.8%)
Discover growth companies
How has Nexstim performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NXTMH has a high level of non-cash earnings.
Growing Profit Margin: NXTMH became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: NXTMH has become profitable over the past 5 years, growing earnings by 30.1% per year.
Accelerating Growth: NXTMH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: NXTMH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2%).
Return on Equity
High ROE: NXTMH's Return on Equity (59.4%) is considered outstanding.
Discover strong past performing companies
How is Nexstim's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: NXTMH's short term assets (€8.9M) exceed its short term liabilities (€2.6M).
Long Term Liabilities: NXTMH's short term assets (€8.9M) exceed its long term liabilities (€3.3M).
Debt to Equity History and Analysis
Debt Level: NXTMH has more cash than its total debt.
Reducing Debt: NXTMH's debt to equity ratio has increased from 49.8% to 63.4% over the past 5 years.
Debt Coverage: NXTMH's debt is well covered by operating cash flow (62.7%).
Interest Coverage: NXTMH earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Nexstim current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NXTMH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NXTMH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NXTMH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NXTMH's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NXTMH has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mikko Karvinen (46 yo)
Mr. Mikko Karvinen, M.Sc. (Econ.), serves as Chief Executive Officer at Nexstim Plc since June 16, 2020 and also served as an Interim Chief Executive Officer at Nexstim Plc since February 11, 2020 until Ju...
Experienced Management: NXTMH's management team is considered experienced (2.6 years average tenure).
Experienced Board: NXTMH's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Nexstim Plc's employee growth, exchange listings and data sources
- Name: Nexstim Plc
- Ticker: NXTMH
- Exchange: HLSE
- Founded: 2000
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €25.771m
- Shares outstanding: 6.69m
- Website: https://www.nexstim.com
Number of Employees
- Nexstim Plc
- ElimAeenkatu 9 B
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NXTMS||OM (OMX Nordic Exchange Stockholm)||Yes||A Shares||SE||SEK||Nov 2014|
|NXTMH||HLSE (OMX Nordic Exchange Helsinki)||Yes||A Shares||FI||EUR||Nov 2014|
|5NX||DB (Deutsche Boerse AG)||Yes||A Shares||DE||EUR||Nov 2014|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/23 00:00|
|End of Day Share Price||2022/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.